Global Seasonal Influenza Vaccines Therapeutics Market Growth, Share, Size, Trends and Forecast (2024 - 2030)

By End User;

Paediatrics, Adolescence, Adults and Elderly.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2020 - 2030).
Report ID: Rn335206775 Published Date: June, 2024 Updated Date: July, 2024

Introduction

Global Seasonal Influenza Vaccines Therapeutics Market (USD Million), 2020 - 2030

In the year 2023, the Global Seasonal Influenza Vaccines Therapeutics Market was valued at USD 9,232.95 million. The size of this market is expected to increase to USD 17,427.68 million by the year 2030, while growing at a Compounded Annual Growth Rate (CAGR) of 9.5%.

The global seasonal influenza vaccines therapeutics market is a critical component of public health strategies worldwide, aimed at mitigating the impact of influenza outbreaks each year. Seasonal influenza, caused by influenza viruses, poses significant health risks and economic burdens due to its potential to cause widespread illness and complications. Vaccination remains the cornerstone of preventive measures against seasonal influenza, driving the demand for influenza vaccines therapeutics globally.

The market dynamics of seasonal influenza vaccines therapeutics are shaped by several factors, including the prevalent strains of influenza viruses identified by health authorities such as the World Health Organization (WHO). These strains guide the formulation of vaccines, which are typically updated annually to ensure efficacy against the circulating viruses. The market is characterized by a coordinated effort between pharmaceutical companies, healthcare providers, and governmental bodies to enhance vaccination coverage and address emerging challenges posed by influenza outbreaks.

The seasonal influenza vaccines therapeutics market is witnessing advancements in vaccine technologies and production processes. These innovations aim to improve vaccine efficacy, broaden strain coverage, and enhance vaccine delivery mechanisms. Additionally, increasing awareness campaigns and government initiatives to promote vaccination uptake further bolster market growth. As healthcare systems strive to minimize the impact of influenza on population health and reduce healthcare costs associated with influenza-related complications, the demand for seasonal influenza vaccines therapeutics continues to evolve globally.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By End User
    2. Market Snapshot, By Region
  4. Global Seasonal Influenza Vaccines Therapeutics Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increasing Awareness
        2. Rising Geriatric Population
        3. Government Initiatives
        4. Technological Advancements
      2. Restraints
        1. Vaccine Manufacturing Challenges
        2. Vaccine Hesitancy
        3. Seasonal Variability
        4. Regulatory Hurdles
      3. Opportunities
        1. Emerging Markets
        2. Strain Improvement
        3. Collaborations
        4. Personalized Vaccines
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Seasonal Influenza Vaccines Therapeutics Market, By End User, 2020 - 2030 (USD Million)
      1. Paediatrics
      2. Adolescence
      3. Adults
      4. Elderly
    2. Global Seasonal Influenza Vaccines Therapeutics Market, By Geography, 2020 - 2030 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Sanofi Pasteur
      2. GlaxoSmithKline (GSK)
      3. Seqirus (a subsidiary of CSL Limited)
      4. AstraZeneca
      5. Pfizer Inc.
      6. Novavax, Inc.
      7. Mitsubishi Tanabe Pharma Corporation
      8. Daiichi Sankyo Company, Limited
      9. Bharat Biotech
      10. Moderna, Inc.
  7. Analyst Views
  8. Future Outlook of the Market